Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGL-3196 and Clopidogrel Interaction Study
NCT04671069Phase 1Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of resmetirom in Nonalcoholic steatohepatitis (NASH), sponsored by Madrigal Pharmaceuticals. Primary endpoints: Area Under the Curve at 14 days and Maximum Plasma Concentration at 14 days. Started Jul 2019; status: completed.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04671069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671069.